Patterns and Trends in the Use of Medications for COPD Control in a Cohort of 9476 Colombian Patients, 2017–2019

References

• GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir med. 2017;5(9):691–706. doi:10.1016/s2213-2600(17)30293-x
   PubMed Web of Science ®Google Scholar
• GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available from: https://goldcoped.org/. Accessed July 21, 2023.
   Google Scholar
• Caballero A, Torres-Duque CA, Jaramillo C, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest. 2008;133(2):343–349. doi:10.1378/chest.07-1361
   PubMed Web of Science ®Google Scholar
• Kuzmar I, Giraldo CO, Acevedo GO, Rua GS. Morbilidad de la enfermedad pulmonar obstructiva crónica en Colombia. Resultados del estudio SANEPOC-2. Revista de la Facultad de Ciencias Médicas. 2017;75(1):19–24.
   Google Scholar
• Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/s0140-6736(17)31222-9
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Nuñez A, Solntseva I, et al. Treatment Pathways Before and After Triple Therapy in COPD: a Population-based Study in Primary Care in Spain. Arch Bronconeumol. 2021;57(3):205–213. doi:10.1016/j.arbres.2020.07.032
   PubMed Web of Science ®Google Scholar
• Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Am J Respir Crit Care Med. 2023;207(7):819–837. doi:10.1164/rccm.202301-0106PP
   PubMed Web of Science ®Google Scholar
• Petite SE. Characterization of chronic obstructive pulmonary disease prescribing patterns in the United States. Pulmonary Pharmacol Therapeutics. 2018;49:119–122. doi:10.1016/j.pupt.2018.02.003
   PubMed Web of Science ®Google Scholar
• Machado-Alba JE, Moreno Gutiérrez PA, Bañol Giraldo AM. Patrones de prescripción de broncodilatadores y corticoides inhalados en pacientes adultos de Colombia. Acta Medica Colombiana. 2015;40:218–226.
   Google Scholar
• Ministerio de Salud y Protección Social. República de Colombia. Resolución 5857 de 2018. Available from: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%205857%20de%202018.pdf. Accessed July 21, 2023.
   Google Scholar
• Ministerio de Salud y Protección Social. República de Colombia. Resolución 1885 de 2018. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/resolucion-1885-de-2018.pdf. Accessed July 21, 2023.
   Google Scholar
• Gil-Rojas Y, Duque-Torres CAT, Del Carmen Figueredo M, et al. Estimación de la prevalencia de EPOC en Colombia a partir del Registro Individual de Prestaciones de Servicios de Salud (RIPS). Revista Colombiana de Neumología. 2019;31(1):564.
   Google Scholar
• Ding B, Kallenbach L, Slipski L, Wilk A, O’Brien D, Guranlioglu D. Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice. Int J Chron Obstruct Pulmon Dis. 2020;15:775–786. doi:10.2147/copd.S238408
   PubMed Web of Science ®Google Scholar
• Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. doi:10.1111/resp.12660
   PubMed Web of Science ®Google Scholar
• Sá-Sousa A, Amaral R, Almeida R, Freitas A, Almeida Fonseca J. Prescribing patterns of medication for respiratory diseases - cluster analysis of the Portuguese electronic prescription database. Eur Ann Allergy Clin Immunol. 2021. doi:10.23822/EurAnnACI.1764-1489.186
   PubMedGoogle Scholar
• Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2015(9):Cd009552. doi:10.1002/14651858.CD009552.pub3
   PubMedGoogle Scholar
• Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: a Review of the 2018 GOLD Report. Mayo Clinic Proceedings. 2018;93(10):1488–1502. doi:10.1016/j.mayocp.2018.05.026
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Eng J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–229. doi:10.1001/archinternmed.2008.550
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. doi:10.2147/copd.S172240
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(20):2407–2416. doi:10.1001/jama.2008.717
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bailey W, Crater G, Emmett A, O’Dell DM, Yawn B. Disease severity and symptoms among patients receiving monotherapy for COPD. Prim Care Respir J. 2011;20(1):46–53. doi:10.4104/pcrj.2010.00059
   PubMedGoogle Scholar
• Xu X, Milea D, Navarro Rojas AA, et al. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand. Int J Chron Obstruct Pulmon Dis. 2021;16:1835–1850. doi:10.2147/copd.S295183
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;2002(4):Cd003902. doi:10.1002/14651858.Cd003902
   PubMedGoogle Scholar
• Devereux G, Cotton S, Fielding S, et al. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: a Randomized Clinical Trial. JAMA. 2018;320(15):1548–1559. doi:10.1001/jama.2018.14432
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Eng J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Jiang L, Kendzerska T, Aaron SD, et al. Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: a Real-World Population Study. Copd. 2022;19(1):315–323. doi:10.1080/15412555.2022.2087616
   PubMedGoogle Scholar